Which drug is safer for the heart after delivery? new study investigates

NCT ID NCT03899961

Completed Knowledge-focused Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study compared the heart effects of two drugs, oxytocin and carbetocin, given to prevent bleeding after childbirth. Researchers measured a heart injury marker (troponin I) in 240 healthy pregnant women after delivery. The goal was to see if carbetocin might be less harmful to the heart than oxytocin, which could help guide treatment choices for women with heart conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carbetocin and oxytocin (drugs given after childbirth to prevent bleeding)
What this could lead to: If carbetocin is shown to be safer for the heart, it could become the preferred drug for preventing bleeding after delivery, especially in women with heart conditions.
What could go wrong: This is a completed Phase 4 trial, but it only looked at a marker of heart injury (troponin I) in healthy women, not actual heart problems or long-term outcomes. The results may not apply to women with heart disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemorrhage pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREGNANCY COMPLICATIONS

Contacts and locations

Locations

Akershus University Hospital

Lørenskog, Norway
Division of Anaesthesia and Intensive Care Medicine, Oslo University Hospital - Rikshospitalet

Oslo, 0027, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.